Search the Newsreel

AURA: Fully enrolled Phase 3 trial and strategic focus on ocular oncology extend cash runway to 1H 2029

Aura Biosciences (AURA) has fully enrolled its Phase 3 Compass trial for bel-sar in early choroidal melanoma, with topline data anticipated in the second half of 2027. The company's strategic shift to ocular oncology has extended its cash runway into the first half of …

Harvard Bioscience Q2 Revenue Rises 11 Percent to $22.7 Million

Harvard Bioscience (HBIO) reported an 11% increase in Q2 2026 revenue, reaching $22.7 million, despite a GAAP net loss of $2.9 million. The company also raised its full-year 2026 revenue guidance to 3% to 5% growth. Insider trading data shows multiple purchases of HBIO …

Harvard Bioscience Lifts 2026 Revenue Outlook After 11% Q2 Growth

Harvard Bioscience (HBIO) reported an 11% year-over-year revenue increase to $22.7 million in Q2 2026, leading them to raise their full-year 2026 revenue growth guidance to 3-5%. Despite a widened GAAP net loss, adjusted EBITDA saw growth, and the company provided Q3 2026 revenue …

Alamar Biosciences, Inc. Stock 12‑Month Price Target Raised to $33.4, Implies 19% Upside

Alamar Biosciences, Inc.'s average 12-month price target has been increased from $31.8 to $33.4 by 5 analysts, with forecasts ranging from $31 to $35 per share. This new target implies approximately 19% potential upside based on the August 10 closing price. The consensus rating …

Gufic Biosciences Q1 Results: Earnings call scheduled for Aug 17

Alamar Biosciences, Inc. 2Q 2026: Revenue $29.4M, EPS $(0.22) — 10-Q Summary

Alamar Biosciences, Inc. reported its second-quarter 2026 results, showing revenue of $29.4 million, an 82% increase year-over-year, driven by a surge in consumables sales. Despite this growth, the company recorded a net loss of $13.2 million and a diluted loss per share of $(0.22). …

Twist Bioscience Corporation (TWST) Stock Analysis: Navigating Uncharted Valuation Waters with Promising Revenue Growth

Harmony Biosciences Holdings (HRMY) Stock Analysis: Exploring an 18% Potential Upside with Strong Revenue Growth

Harmony Biosciences Holdings, Inc. $HRMY Shares Sold by Janus Henderson Group PLC

Dimensional Fund Advisors LP Acquires 277,051 Shares of Solid Biosciences Inc. $SLDB

Dimensional Fund Advisors LP has increased its stake in Solid Biosciences Inc. (NASDAQ:SLDB) by 40.8%, purchasing an additional 277,051 shares to now own 956,135 shares valued at approximately $6.88 million. Institutional investors collectively hold 81.46% of SLDB. The company recently reported a quarterly loss …

Twist Bioscience (NASDAQ:TWST) Reaches New 1-Year High - Here's What Happened

Twist Bioscience (NASDAQ:TWST) reached a new 52-week high, trading as high as $121.50, despite its average analyst price target being below current trading levels. The company reported higher-than-expected revenue but a wider adjusted loss per share. While institutional investors have increased their holdings, company …

DTIL Q2 2026 Earnings: Wider-than-Expected Loss Highlights Clinical-Stage Biotech Challenges - GAAP Earnings Report

Alamar Biosciences (ALMR) Earnings Date and Reports 2026

Sagimet Biosciences (SGMT) Earnings Date and Reports 2026

Precision BioSciences Inc (DTIL) Earnings Forecast: Future EPS & Revenue Growth Estimates

How (IDYA) Movements Inform Risk Allocation Models

This article from Stock Traders Daily discusses how Ideaya Biosciences Inc. (NASDAQ: IDYA) movements inform risk allocation models. It highlights key findings such as a strong near-term sentiment possibly leading to a long-term positive bias, and an exceptional 49.4:1 risk-reward setup. The analysis provides …

Rua Bioscience Issues New Warrants as Part of Debt Facility Roll-Over

Empery Asset Management, LP Initiates Position in Cellectar Biosciences Inc (CLRB)

Empery Asset Management, LP has initiated a new position in Cellectar Biosciences Inc (CLRB) by purchasing 864,090 shares, representing 2.81% of its portfolio. This investment reflects Empery's focus on small-cap healthcare companies, despite CLRB's significant stock decline and poor financial health. Cellectar Biosciences is …

Truist Adjusts Price Target on MBX Biosciences to $88 From $70, Maintains Buy Rating

Truist Securities has increased its price target for MBX Biosciences to $88, up from the previous $70, while reiterating a Buy rating on the company's stock. This adjustment reflects a more optimistic outlook by the analyst firm regarding MBX Biosciences' future performance.

Emergent BioSolutions cuts FY2026 revenue forecast, triggering securities investigation.

Emergent BioSolutions has significantly lowered its FY2026 revenue guidance, leading to a sharp decline in its stock price and a securities investigation by Levi & Korsinsky. The law firm is examining whether the company's prior optimistic forecasts were misleading, encouraging investors who suffered losses …

Alamar outlines $116M-$120M 2026 revenue outlook while targeting 100+ instruments and $400,000+ pull-through

Earnings Call Insights: Alamar Biosciences (ALMR) Q2 2026 MANAGEMENT VIEW * “Q2 2026 was a strong quarter that reflects the momentum of our business,” said Co-Founder, Chairman & CEO Yuling Luo, highlighting that “Total revenue grew 82% year-over-year,” that “Consumable revenue accounted for 53% …

Jade Biosciences, Inc. Stock 12‑Month Price Target Raised to $46.44, Implies 111% Upside

Analysts have raised the average 12-month price target for Jade Biosciences, Inc. (JBIO) stock from $45.89 to $46.44, with individual forecasts ranging from $25 to $77 per share. This new target suggests a potential upside of approximately 111% from the Aug. 7 closing price. …

Arcadia Biosciences, Inc. SEC Filing (Aug 10, 2026)

This article reports on an SEC filing by Arcadia Biosciences, Inc. (RKDA) on August 10, 2026. The filing is an ARS type and its impact is assessed as low with a neutral sentiment. The document is available as a PDF and further details about …

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results

Cogent Biosciences reported strong second-quarter 2026 financial results and significant business highlights, including progress toward potential FDA approvals for bezuclastinib for GIST and NonAdvSM later this year. The company also announced the successful onboarding of a cross-functional customer-facing team and a robust pro forma …

TWST shareholder (NASDAQ: TWST) files to sell 113,318 common shares

Emily M. Leproust, a shareholder of Twist Bioscience Corp (NASDAQ: TWST), has filed a Form 144 notice indicating her intent to sell 113,318 shares of common stock through Fidelity Brokerage Services LLC. The aggregate market value of this proposed sale is $14,183,056.89, with the …

Emergent BioSolutions Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Emergent BioSolutions (EBS)

Levi & Korsinsky, LLP is investigating Emergent BioSolutions (EBS) for potential securities law violations after the company significantly cut its FY2026 revenue guidance. The firm encourages investors who lost money on EBS shares to submit their loss information for a free evaluation of their …

Ensysce Biosciences (ENSC) officer reports 154.8M underlying common via preferred

Ensysce Biosciences' President, James William Morrison, reported an indirect holding of 154,821 Series C Non-Voting Convertible Preferred Stock shares through Belgarion Ventures Ltd. These preferred shares are convertible into 154,821,000 common shares, contingent on stockholder approval and Nasdaq rules, with a beneficial ownership limitation. …

Alamar Biosciences FY26 sales guidance beats estimates

Alamar Biosciences (NASDAQ: ALMR) reported strong Q2 2026 results with an 82% revenue surge to $29.4 million, primarily driven by a 147% increase in consumable sales. The company raised its full-year 2026 revenue guidance to $116-$120 million, surpassing analyst estimates. Despite a widening net …

Cellectar Biosciences Sets Major Conference Schedule: Pediatric Cancer Data Featured

Cellectar Biosciences (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company, announced its participation in five major medical and industry conferences throughout September 2025. COO Jarrod Longcor will present on the company's Phospholipid Drug Conjugate™ (PDC) platform, including its lead asset iopofosine I 131, with notable …

Cogent Biosciences (COGT) files prospectus for $400M at-the-market stock program

Cogent Biosciences (COGT) has filed a prospectus supplement for an at-the-market (ATM) stock program, allowing it to offer and sell up to $400 million of its common stock. This program uses an existing automatic shelf registration statement and permits sales through Guggenheim Securities, LLC. …

Alamar Biosciences expands proteomics partnership by 86,000 samples

Alamar Biosciences is expanding its partnership with the Alzheimer’s Disease Data Initiative and Gates Ventures to analyze an additional 86,000 plasma samples using its NULISAseq Neuro 220 panel. This expansion builds on a previous initiative that profiled over 55,000 samples, aiming for a total …

Lexaria Bioscience Received Notice of Delisting

Lexaria Bioscience (LEXX) received a delisting notice from Nasdaq on August 4, 2026, due to non-compliance with the $1.00 minimum bid price rule. The company has requested a hearing, which temporarily stays the delisting. Following an August 3 reverse stock split, LEXX's stock price …

OrbiMed trims MBX Biosciences (MBX) position to 6.4% after share sales

OrbiMed Advisors and its affiliates have reduced their beneficial ownership in MBX Biosciences (MBX) to 6.4%, down from a previous stake, following a series of open-market share sales between June 29 and August 7, 2026. The sales, executed at prices ranging from $53.48 to …

Alamar: Q2 Earnings Snapshot

Cogent Biosciences (NASDAQ: COGT) details cash runway and bezuclastinib FDA timelines

Cogent Biosciences (NASDAQ: COGT) has provided updates on its financial runway and the FDA timelines for its drug bezuclastinib. The company reported a net loss of $96.4 million for Q2 2026, widening from the previous year, but has $792.3 million in cash, cash equivalents, …

Alamar Biosciences Reports Second Quarter 2026 Financial Results and Provides 2026 Revenue Guidance

Alamar Biosciences reported strong second-quarter 2026 financial results, with total revenue increasing by 82% to $29.4 million and consumable revenue growing by nearly 150% year-over-year. The company also launched new products, including a multiplexed immunoassay for eMTBR-tau and the NULISAseq™ Immune 340 Panel, and …